60755-80-8Relevant academic research and scientific papers
Synthesis of deuterium-labelled (-)-galanthamine
Rouleau, Julien,Guillou, Catherine
, p. 236 - 238 (2008/12/20)
The synthesis of deuterium-labelled galanthamine is reported. 6-[ 2H3]methoxy-N-[2H3]methyl-(-)- galanthamine was obtained in seven steps from galanthamine. The synthesis was carried out by selective O- and N-de
Synthesis and in vitro evaluation of galanthamine derivatives for examination of nicotinic acetylcholine receptor system
Schildan, A.,Schirrmacher, R.,Samochocki, M.,Christner, C.,Mmaelicke, A.,Roesch, F.
, p. S247 - S249 (2007/10/03)
The synthesis and radioactive labeling of several galanthamine derivatives, 6-O-demethyl-6-O-fluoroethylgalanthamine, 10-N-demethyl-10-N-fluoroethylgalanthamine and N-methylgalanthaminium are reported. First in vitro evaluation were carried out to determine their properties as allosterically potentiating ligands of nicotinic receptors. N-methylgalanthaminium was found to be a promising candidate for further investigations.
Potent acetylcholinesterase inhibitors: Design, synthesis, and structure - Activity relationships of bis-interacting ligands in the galanthamine series
Mary, Aude,Renko, Dolor Zafiarisoa,Guillou, Catherine,Thal, Claude
, p. 1835 - 1850 (2007/10/03)
New galanthamine derivatives, especially bis-interacting ligands 3-5 and 7-9 were prepared in order to interact with the catalytic and the peripheral sites of acetylcholinesterase (AChE). The synthesis, the anticholinesterase activities, and the structure-activity relationships of bis-interacting ligands are reported. Compounds 4d-e were found to be more potent than galanthamine and tacrine in inhibiting AChE. Copyright (C) 1998 Elsevier Science Ltd.
Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer's disease ?
Han, SY,Sweeney, JE,Bachman, ES,Schweiger, EJ,Forloni, G,et al.
, p. 673 - 687 (2007/10/02)
We conducted structural and pharmacological studies of galanthamine, a cortical acetylcholinesterase (AChE) inhibitor, and 19 structural analogs.Systematic derivatization of galanthamine at the cyclohexene ring, tertialy amino, hydroxyl, methoxyl functions indicated that these structural features are essential for biological activity.Molecular modeling studies suggested that the low energy conformations of the analogs are similar to that of the parent.One derivative, galanthamine n-butyl carbamate, had an LD50 of over 100 mg/kg (ip) in mice.In a passive avoidanceparadigm, this analog improved performance in a dose-dependant fashion with a peak effect at 0.1 mg/kg in control and 0.5 mg/kg in basal forebrain lesioned mice.In the same paradigm, the peak effect of the parent compound is a 6-fold higher dose.With this surprisingly high therapeutic ratio, this compound may be of interest in treating cholinergic deficits of the central nervous system such as Alzheimer's desease. galanthamine derivatives / molecular modeling / avetylcholinesterase inhibitor / Alzheimer's desease / passive avoidance / basal forebrain lesion
